Market Access News | pharmaphorum

News

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.

News

FDA approves PureTech's obesity device Plenity

The FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting it up to rival Novo Nordisk in this lucrative market.

News

Sandoz to commercialise opioid induced constipation tablet i...

As it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi to commercialise Rizmoic (naldemedine) in the key European markets

News

Indivior stung by fraud charges over US marketing

Shares in UK drugmaker Indivior have gone into freefall after it was charged by the US Department of Justice for fraudulently marketing its opioid addiction treatment.

News

Drug middlemen point finger at pharma in US pricing debate

The so-called ‘middlemen’ in the US pharma supply chain have blamed big pharma for skyrocketing drug prices in the country, as the Senate Finance Committee grilled them over the deals they strik

News

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

FDA approves PureTech's obesity device Plenity

Sandoz to commercialise opioid induced constipation tablet i...

Indivior stung by fraud charges over US marketing

Drug middlemen point finger at pharma in US pricing debate

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

Dismay as FDA blocks Regenxbio's Hunter syndrome therapy

How to meet your physicians where they are online

News

Editor's Picks